ABN AMRO Bank N.V. Makes New $136.50 Million Investment in Danaher Corporation $DHR

Key Points

• ABN AMRO Bank N.V. acquired 189,788 Danaher shares worth approximately $136.5 million in the second quarter, making DHR its 15th-largest holding and representing about 1.8% of its portfolio.
• Analysts maintain a generally positive view, with Danaher receiving a “Moderate Buy” consensus rating and an average price target of $228.91, despite several recent target-price reductions.
• Danaher’s latest quarterly results exceeded expectations: EPS came in at $1.94 versus $1.85 expected, while revenue reached $6.26 billion and rose 5.5% year over year.

ABN AMRO Bank N.V. acquired a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 189,788 shares of the conglomerate's stock, valued at approximately $136,505,000. Danaher comprises about 1.8% of ABN AMRO Bank N.V.'s investment portfolio, making the stock its 15th largest position.

A number of other institutional investors have also recently made changes to their positions in the company. Main Street Group LTD bought a new stake in Danaher in the first quarter worth $25,000. JPL Wealth Management LLC bought a new position in Danaher during the third quarter valued at $25,000. Elevated Capital Advisors LLC purchased a new position in shares of Danaher in the 4th quarter worth $26,000. WFA of San Diego LLC purchased a new position in shares of Danaher in the 2nd quarter worth $26,000. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of Danaher in the 4th quarter worth about $27,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on DHR shares. HSBC decreased their target price on shares of Danaher from $270.00 to $230.00 and set a "buy" rating on the stock in a research report on Wednesday, June 3rd. Royal Bank Of Canada lifted their price target on Danaher from $200.00 to $215.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 22nd. Wall Street Zen cut Danaher from a "buy" rating to a "hold" rating in a research note on Saturday, April 25th. UBS Group lowered their price objective on Danaher from $270.00 to $250.00 and set a "buy" rating for the company in a research note on Wednesday, April 22nd. Finally, Argus dropped their target price on Danaher from $265.00 to $230.00 and set a "buy" rating for the company in a report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Danaher has an average rating of "Moderate Buy" and an average price target of $228.91.

Danaher Trading Down 0.7%

DHR opened at $202.51 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock's 50 day moving average price is $193.14 and its 200-day moving average price is $193.21. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The stock has a market cap of $142.37 billion, a price-to-earnings ratio of 35.97, a P/E/G ratio of 2.52 and a beta of 0.78.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.Danaher's quarterly revenue was up 5.5% compared to the same quarter last year. During the same period last year, the company earned $0.77 EPS. On average, equities analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Profile

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source